• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

124
16
12
10
9

COUNTRY

4
4
3
3
2

PRICE

91
121
262
449

PUBLISHED

39
49
109
449

PRODUCT TYPE

442
6
1

Immune Disorders

More than 150 primary immunodeficiency diseases (PIDs) have been identified, a number that does not include acquired immunodeficiencies. Examples of immune disorders include Type 1 diabetes, rheumatoid arthritis, allergies, Crohn’s Disease, and HIV, which infects over 0.5% of the world’s population.

In the reports and subscriptions listed under Research and Markets’ category you will find pipeline assessments of drugs and therapeutics, market forecasts, investment and growth opportunities, and much more. Also explored in-depth is the key role of immune response and pharmaceuticals in transplant medicine, with reviews of clinical trials, market trends and major companies in the areas of lung transplants, liver transplants, transplant inflammation/rejection, etc.

Key players profiled include Abbott Laboratories, Pfizer, Johnson & Johnson, Biogen Idec, Amgen, Bayer AG, Sanofi, and more. Show Less
Read more

PRODUCT TITLE

PharmaPoint: Crohn's Disease - Canada Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn’s Disease - Canada Drug Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These...

January 2014
FROM

Cimzia (Crohn's Disease) - Forecast and Market Analysis to 2022

Cimzia (Crohn’s Disease) - Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will...

January 2014
FROM

Vercirnon (Crohn's Disease) - Forecast and Market Analysis to 2022

Vercirnon (Crohn’s Disease) - Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds...

January 2014
FROM

PharmaPoint: Crohn's Disease - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn’s Disease - Japan Drug Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These...

January 2014
FROM

Lupus Nephritis Global Clinical Trials Review, H1, 2014

Lupus Nephritis Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, “Lupus Nephritis Global Clinical Trials Review, H1, 2014" provides data on the Lupus Nephritis clinical trial...

January 2014
FROM

PharmaPoint: Crohn's Disease - China Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn’s Disease - China Drug Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These...

January 2014
FROM

Prochymal (Crohn's Disease) - Forecast and Market Analysis to 2022

Prochymal (Crohn’s Disease) - Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds...

January 2014
FROM

Stelara (Crohn's Disease) - Forecast and Market Analysis to 2022

Stelara (Crohn’s Disease) - Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will...

January 2014
FROM

PharmaPoint: Crohn's Disease - US Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn’s Disease - US Drug Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds...

January 2014
FROM

Remicade (Crohn's Disease) - Forecast and Market Analysis to 2022

Remicade (Crohn’s Disease) - Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will...

January 2014
FROM

Tysabri (Crohn's Disease) - Forecast and Market Analysis to 2022

Tysabri (Crohn’s Disease) - Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will...

January 2014
FROM

PharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn’s Disease - Global Drug Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon, such...

January 2014
FROM

PharmaPoint: Crohn's Disease - 5EU Drug Forecast and Market Analysis to 2022

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon These compounds will challenge the current biologics in an attempt to dislodge the stronghold...

January 2014
FROM

PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

PharmaPoint: Crohn’s Disease - India Drug Forecast and Market Analysis to 2022 Summary The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These...

January 2014
FROM

Acute Inflammation - Pipeline Review, H2 2013

Acute Inflammation - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Acute Inflammation - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

December 2013
FROM

Food Allergy - Pipeline Review, H2 2013

Food Allergy - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Food Allergy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

December 2013
FROM

Myasthenia Gravis - Pipeline Review, H2 2013

Myasthenia Gravis - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Myasthenia Gravis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

December 2013
FROM

Cedar Pollen Allergy - Pipeline Review, H2 2013

Cedar Pollen Allergy - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Cedar Pollen Allergy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

December 2013
FROM

Sarcoidosis - Pipeline Review, H2 2013

Sarcoidosis - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Sarcoidosis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

December 2013
FROM

Birch Pollen Allergy - Pipeline Review, H2 2013

Birch Pollen Allergy - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Birch Pollen Allergy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This...

December 2013
FROM
Loading Indicator

Our Clients

Our clients' logos